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Stepped Wedge Designs: insights from a design
of experiments perspective
J. N. S. Matthewsa∗, A. B. Forbesb
Stepped wedge designs (SWDs) have received considerable attention recently, as they are potentially a useful way
to assess new treatments in areas such as health services implementation. Because allocation is usually by cluster,
SWDs are often viewed as a form of cluster-randomized trial. However, since the treatment within a cluster changes
during the course of the study they can also be viewed as a form of crossover design. This article explores SWDs
from the perspective of crossover trials, and designed experiments more generally. We show that the treatment
effect estimator in a linear mixed effects model can be decomposed into a weighted mean of the estimators
obtained from i) regarding a SWD as a conventional row-column design, and ii) a so-called vertical analysis,
which is a row-column design with row effects omitted. This provides a precise representation of “horizontal” and
“vertical” comparisons, respectively, which to date have appeared without formal description in the literature. This
decomposition displays a sometimes surprising way the analysis corrects for the partial confounding between time
and treatment effects. The approach also permits the quantification of the loss of efficiency caused by mis-specifying
the correlation parameter in the mixed-effects model. Optimal extensions of the vertical analysis are obtained
and these are shown to be highly inefficient for values of the within-cluster dependence which are likely to be
encountered in practice. Some recently described extensions to the classic SWD incorporating multiple treatments
are also compared using the experimental design framework.
Copyright c© 201? John Wiley & Sons, Ltd.
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1. Introduction
Stepped wedge designs (SWDs) have recently received an increasing amount of attention, largely as a design for the
evaluation of service delivery and implementation [1, 2]. The typical design, shown in Table 1 for six time periods and
five sequences, denoted by SW(5), reveals the key features of the basic SWD: the trial is divided into successive time
periods and into sequences, with the experimental units being randomly allocated to one of the sequences. All sequences
start with the standard treatment in the first period and then change to the new treatment in a subsequent period, the
change-over occurring at different times in the different sequences, but with the new treatment administered in the final
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period of all sequences. The number of sequences in these designs corresponds to the number of ‘steps’, i.e. occasions
on which the standard treatment changes to the new [3]. Features which make the design attractive for the assessment of
service implementation are i) that all sequences start with the standard and finish with the new treatment and ii) once the
changeover to the new treatment has occurred it is impossible to revert to the standard treatment.
Time
Sequence 1 2 3 4 5 6
1 0 1 1 1 1 1
2 0 0 1 1 1 1
3 0 0 0 1 1 1
4 0 0 0 0 1 1
5 0 0 0 0 0 1
Table 1. Standard stepped wedge design, SW(5), with T = 6 periods and S = 5 sequences comparing treatments 0
(standard) and 1 (new).
The experimental units are usually groups or clusters of patients, such as general practices, hospitals, care homes, rural
communities or schools, rather than individual patients [1, 2]. Consequently SWDs are often viewed as a variant of the
standard cluster-randomized trial. While many aspects of SWDs can profitably be seen in this light, the fact that they are
divided into successive treatment periods and units are allocated to sequences of treatments, means that they also have
much in common with crossover (CO) trials [4]. The purpose of this paper is to explore the extent to which the perspective
of COs and, more generally, classical designed experiments, can illuminate statistical aspects of SWDs. For example, the
literature on SWDs has loosely described ‘horizontal’ and ‘vertical’ comparisons (see, e.g., [5]) but without those being
defined formally. We show that these can be defined explicitly using experimental design concepts and language.
In the next section we provide background on classical row-column designs and their relationship to SWDs. Section
3 provides a decomposition of the stepped wedge (SW) treatment effect under a linear mixed model with a variety of
dispersion structures. Section 4 derives the variance of the SW treatment effect estimators under the correct and mis-
specified models of the dispersion structure, and examines the impact of mis-specification. In Section 5 we derive optimal
weights for the so-called ‘vertical’ analyses and Section 6 considers recently proposed extensions to multiple treatments
and derives the relative efficiency of treatment effect estimators under different designs. The paper concludes with a
discussion of the issues raised.
2. Stepped wedge designs as a classical row-column designs
The principal concerns for analyses of SWDs is that account should be taken of i) the fact that the designs extend over time
and so there may be systematic time effects in the observed responses, and ii) that individual responses clustered within
higher levels units are correlated. In the analysis of a CO study there are analogous concerns which are addressed by the
use of period and patient effects. In addition the literature on CO designs often considers a term for the carryover effect of
treatments but, for many medical applications, the appropriateness of the standard carryover model has been questioned
(see [6]). For SWDs there are issues related to carryover [7] but they are of a somewhat different character and we will
defer discussion of these until Section 7. Recent usage of CO designs in medical applications excludes carryover by using
washout periods and in these circumstances a carryover term is not present in the model, so crossover designs are then
essentially row-column designs, which we now describe.
In a row-column design, such as a Latin square or a Youden design, the aim is to arrange the treatments amongst the
rows and columns so that i) the study can provide estimates of the treatment effects, notwithstanding the presence of row
and column effects, and ii) that these estimates should have the best precision possible. Row-column designs in which
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each treatment is replicated as nearly equally as possible within each row, and also within each column, will provide high
precision estimates, and are often optimal with respect to appealing criteria. The most familiar example of an optimal
row-column design is the Latin Square, but there are many more flexible row-column designs with optimal properties,
such as Generalized Youden Designs (GYDs) (see, e.g. chapter 4 of [8]). Consider, for example, the two-treatment GYD
shown in Table 2, where each treatment appears three times in each row and two or three times in each column (i.e. as
nearly equally as possible): denote this design as NrO. Row and column effects can be eliminated from the treatment
comparison in both SW(5) and NrO, but the more balanced layout of NrO allows this to be done more efficiently, and it is
worth considering for a moment the details of how this is achieved.
Time
Sequence 1 2 3 4 5 6
1 1 0 1 0 1 0
2 0 1 0 1 0 1
3 1 0 1 0 1 0
4 0 1 0 1 0 1
5 1 0 1 0 1 0
Table 2. A Generalized Youden Design, denoted NrO, with S = 5 rows and T = 6 columns, having the same treatment
replication as SW(5).
When contrasting SWDs and row-column designs a notation that is more commonly seen with the former than the latter
will be adopted. Therefore the rows will be indexed by s = 1, . . . , S, as these correspond with sequences in the SWD,
and columns are indexed by t = 1, . . . , T as these correspond to successive periods, or time. If a single outcome Yst were
observed in row s and column t of the designs in Tables 1 and 2, then the usual model for a row-column design, adapted
for the two-treatment case, is
Yst = αs + βt +Dstθ + ηst (1)
with fixed row effects αs, fixed column effects βt, treatment indicator Dst ∈ {0, 1}, and mutually independent errors ηst
with mean 0 and variance σ2η. In the statistics literature, as well as the econometrics literature for panel data, such a model
is called a two-way fixed effects model. The least squares estimator of the treatment effect θ is a linear combination of the
observations,
θˆ =
∑
s,t
aRCst Yst,
where the set of values aRCst , which we refer to as the coefficient matrix, are shown in Table 3 for the SW(5) and NrO
designs. The superscript RC denotes that the coefficient matrix arises from the model (1), which includes row and column
effects: the derivation of the aRCst is outlined in Appendix 1.
Time
Sequence 1 2 3 4 5 6
1 -10 14 8 2 -4 -10
2 -5 -11 13 7 1 -5
3 0 -6 -12 12 6 0
4 5 -1 -7 -13 11 5
5 10 4 -2 -8 -14 10
(a) Scaled coefficients for SW(5): above are 70aRCst
Time
Sequence 1 2 3 4 5 6
1 2 -2 2 -2 2 -2
2 -3 3 -3 3 -3 3
3 2 -2 2 -2 2 -2
4 -3 3 -3 3 -3 3
5 2 -2 2 -2 2 -2
(b) Scaled coefficients for NrO: above are 36aRCst
Table 3. Scaled coefficient matrices for designs SW(5) and NrO
The coefficients in Table 3 sum to zero down the columns, thereby eliminating column effects βt, and the rows sum to
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zero, eliminating the fixed row effects αs from θˆ. Moreover, there is a symmetry to a standard stepped wedge design: if
time were reversed in Table 1, then the design obtained would be the same as SW(5), but with 0s and 1s interchanged and
the sequences written in the order 5 to 1. As the model (1) is temporally reversible, there is a corresponding anti-symmetry
of the aRCst in Table 3(a), where reversing the order of the columns and of the rows yields the original matrix multiplied
by -1. Inspection of the elements in Table 3(a) shows that the layout of SW(5) requires that the observations are combined
with very different weights and in a rather unintuitive way: for example Y12 is given fourteen times the weight that is given
to Y25, and Y30 and Y36 are omitted altogether. This feature is attributable to the unbalanced nature of the SWD, in that
treatment and time are partly confounded - something which is less marked for the more balanced design NrO, where the
weights vary much less.
Also,
var(θˆ) =σ2η
∑
(aRCij )
2
= 37σ
2
η = 0.43σ
2
η for SW(5)
= 536σ
2
η = 0.14σ
2
η for NrO
Compared with NrO, which is the optimal design [8] for this number of rows, columns and treatments, the SWD
has efficiency of only 32% (0.14/0.43), which quantifies the substantial loss of efficiency arising from the temporally
imbalanced nature of the SWD.
If the model (1) is amended so that the row term αs is omitted, then the coefficient matrix changes to aCst, as shown in
Table 4 (the corresponding table for NrO is unchanged, as the treatment and row effects are orthogonal in this design).
The variance of this estimator of θ is 1/4σ2η, which is substantially smaller than 3/7σ2η (provided that σ2η has the same value
in both models, as would occur if the model including the αs were inappropriate) and illustrates the penalty which has to
be paid to eliminate simultaneously row and column effects in such an unbalanced design. This is despite the fact that the
coefficients in Table 4 show that the first and last observations in each row are ignored in this estimator. Nevertheless, the
unequal incidence of treatments in each column still exacts a price because this variance is nearly twice that for NrO.
Time
Sequence 1 2 3 4 5 6
1 0 4 3 2 1 0
2 0 -1 3 2 1 0
3 0 -1 -2 2 1 0
4 0 -1 -2 -3 1 0
5 0 -1 -2 -3 -4 0
Table 4. Scaled coefficient matrices for designs SW(5) when the model omits row effects: above are 20aCst
The analysis implied by the coefficients in Table 4 compares the mean of the observations on treatment 0 with the
mean of those on treatment 1, separately within each column. Under the amended model (1) the resulting T column-
wise estimators of θ are independent and Table 4 essentially prescribes how these are to be combined, namely by being
weighted inversely to their variances. Such an analysis closely resembles the the so-called vertical analyses mentioned
in the context of SWDs, see [5]. As is remarked in [5], if observations in successive columns are dependent, it may be
better if the separate column-wise contrasts are combined differently from the way implied in Table 4, a point taken up in
Section 5.
Vertical analyses, being based on within-column contrasts, are sometimes recommended since they preserve the
randomization, because in a SWD units are randomized to rows not columns. As mentioned in [5] this is also true of
analyses based on the coefficients in Table 3(a), which can be viewed as aggregations of within-column contrasts, albeit
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with less obvious weights and the rather counter-intuitive property that some observations receiving the same treatment
receive weights of opposite sign.
3. The Stepped Wedge treatment effect estimator in a linear mixed model
3.1. The repeated cross-sectional sampling case
The link between the above discussion and SWDs as they are usually implemented is not immediate, because the
formulation implied by (1) is not used for SWDs. In particular, clusters, not individuals, are allocated to sequences and
responses within clusters are generally correlated. A more realistic formulation denotes the continuous response of an
individual j, in the ith cluster allocated to sequence s, observed in the tth period by Ysijt: the treatment administered
in that period will depend on the sequence s to which cluster i has been allocated. While the same cluster is repeatedly
measured throughout the study, the question arises of whether the individuals are measured on several occasions or just
once. This will depend on context, as noted by Turner and colleagues [9] in the context of a cluster CO design. For the
moment we assume that the application is such that each individual is measured just once, in a particular cluster and
period, and as such there are separate samples of individuals in each period in each cluster. Also for simplicity it will be
assumed that the same number of individuals, n, are observed in each period in each cluster, and that an equal number
of clusters, N , is allocated to each of the S sequences in the design. A widely used model for the outcomes Ysijt was
proposed by Hussey and Hughes [10], namely
Ysijt = βt +Dstθ + αsi + sijt, s = 1, . . . , S; i = 1, . . . , N j = 1, . . . , n; , t = 1, . . . , T (2)
where the number of periods, T , will be S + 1 for designs such as those in Table 1, although this need not hold for
variations on this design. In this model βt is a fixed period effect, equivalent to the column effect, and Dst is as in (1),
and θ is the treatment effect. The cluster effect is described by a random term αsi (as opposed to the fixed αs in (1)),
independent of the individual residuals sijt; both terms have zero mean and variances τ2 and ν2, respectively.
Estimation of the βt and θ can proceed directly using maximum likelihood if we assume that the random terms in (2)
are Normally distributed, or otherwise using a generalized estimating equation (GEE). However, an equivalent and more
helpful form of the equations for the estimation of βt and θ can be derived by starting from the model implied for the
cluster/period means, Y¯sit =
∑n
j=1 Ysijt/n, namely
Y¯sit = βt +Dstθ + αsi + ¯sit (3)
from which var(Y¯sit) = τ2 + n−1ν2 and cov(Y¯sit, Y¯sit′) = τ2, t 6= t′. Suppose Y¯si = (Y¯si1, . . . , Y¯siT )T denotes the T -
dimensional vector of the means Y¯sit, t = 1, . . . , T and γT = (βT , θ). Then if we write E(Y¯sit) from (3) as Xsγ, where
Xs is the design matrix for the fixed effects, which has a common value for all clusters i allocated to sequence s, then
standard results on mixed models show that
γˆ =
[
S∑
s=1
N∑
i=1
XTs V
−1Xs
]−1 S∑
s=1
XTs V
−1
N∑
i=1
Y¯si
=
[
S∑
s=1
XTs V
−1Xs
]−1 S∑
s=1
XTs V
−1Y¯s, (4)
where Y¯s = N−1
∑N
i=1 Y¯si. Here V is the variance of Y¯si, and although a general form could be envisaged, we focus
on that induced by (3) which is n−1ν2IT + τ2JT,T , where IT is the T × T identity matrix and JT,T ′ is the T × T ′
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matrix of ones. In the following it will often be convenient to write V as σ2((1− ψ)IT + ψJT,T ), with σ2 = n−1ν2 + τ2
and ψ = nτ2/(ν2 + nτ2): note that ψ, the correlation of the cluster-period means, depends on n. This is in contrast
to the usual measure of dependence encountered in cluster randomized trials, the intra-cluster correlation (ICC),
namely ρ = τ2/(ν2 + τ2), the correlation between individuals in the same cluster that is induced by (2). Notice that
ψ = nρ/[(1− ρ) + nρ], so the dependence on n means that ψ can take substantially larger values than are commonly
encountered for ICCs: e.g. ρ = 0.1 corresponds to ψ = 0.36 for n = 5 and to ψ = 0.85 for n = 50.
From (4) it is seen that estimates of βt and θ are appropriate linear combinations of the means of the observations in each
cell of the design in Table 1. An explicit formula for θˆ is given in Appendix 2, where it is also shown that the coefficient
matrix for θˆ from (4), ast, a function of ψ, is a weighted mean of the coefficient matrices for the vertical analysis, aCst, and
the row-column matrix, aRCst , namely
ast =
(1− b)
(1− b) + bQa
C
st +
bQ
(1− b) + bQa
RC
st =
aCst + b(Qa
RC
st − aCst)
1 + b(Q− 1) . (5)
Here b = Tψ/[1 + ψ(T − 1)] = Tnρ/[1 + (Tn− 1)ρ], a quantity which has an important role in [3] (denoted therein by
R), and Q is determined by the layout of the design and is defined in Appendix 1 - for SWDs of the form in Table 1
with T periods, Q = 12 +
1
2T . Note that 0 ≤ b < 1, with b = 0 when τ2 = 0, and b→ 1 as nτ2 →∞. Naturally, as b = 0
corresponds to no cluster effect in (3), the estimator is that from the conventional model with no row effect. On the
other hand, if nτ2 is large, then the between-cluster variation dominates and the smallest variance for θˆ will arise from
estimators that are largely based on within-cluster contrasts, and in the limit as b→ 1 the estimator coincides with that
from the row-column design.
Equation (5) allows coefficient matrices to be computed for any T : in Table 5 we illustrate the cases with six and
four periods. The pattern of coefficients is similar between the four and six period versions: the columns, but not the
rows, always sum to zero; the rows sum to zero only when ψ = 1; when ψ = 0 the first and last periods are ignored. For
intermediate values of ψ the row sums tend to zero as ψ increases, and observations from the first and last periods begin to
contribute to θˆ. Notice that the observations from the first and last periods of the middle sequence (i.e. the sequence with
equal replication of 0 and 1) are ignored in all analyses: this does not apply when T is odd. Note also that for all ψ the
coefficient matrix has symmetry arising from the time-reversible nature of the design, namely ast = −aS+1−s,T+1−t: the
matrices in Table 5 are based on a temporally reversible V , and this symmetry may not obtain if this were not the case.
3.2. Model extensions
The model (2) is suitable for the case where the nT measurements in a cluster arise from nT different individuals, each
measured once. If the nT observations arise from T serial measurements on each of n individuals as would be the case in
a closed cohort design [7], i.e. if the data are longitudinal, then an alternative model is needed. A suitable extension is
Ysijt = βt +Dstθ + αsi + ξsij + sijt, s = 1, . . . , S; i = 1, . . . , N ; j = 1, . . . , n; , t = 1, . . . , T ; (6)
where ξsij is a random effect for each individual, with zero mean and variance ω2, independent of the other random
terms. A further extension is when the period effect can vary randomly between clusters, i.e. βt in (6) is replaced by
βt + φsit, where φsit are independent random variables, also independent of the other random terms and with zero mean
and variance δ2. This would be important if the way time affects the outcome differs between the clusters, for example
because of differences in their location. Both of these elaborations of the model in (6) have been considered by others, e.g.
[3, 11].
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ψ Coefficients SW(5) Coefficients SW(3)
0.0 110

0 2.0 1.5 1.0 0.5 0
0 −0.5 1.5 1.0 0.5 0
0 −0.5 −1.0 1.0 0.5 0
0 −0.5 −1.0 −1.5 0.5 0
0 −0.5 −1.0 −1.5 −2.0 0
 110
0 5.0 2.5 00 −2.5 2.5 0
0 −2.5 −5.0 0

0.05 19

−0.2 1.8 1.3 0.8 0.3 −0.2
−0.1 −0.6 1.4 0.9 0.4 −0.1
0.0 −0.5 −1.0 1.0 0.5 0.0
0.1 −0.4 −0.9 −1.4 0.6 0.1
0.2 −0.3 −0.8 −1.3 −1.8 0.2
 191
−4.5 45.5 20.5 −4.50.0 −25.0 25.0 0.0
4.5 −20.5 −45.5 4.5

0.1 110

−0.4 2.0 1.4 0.8 0.2 −0.4
−0.2 −0.8 1.6 1.0 0.4 −0.2
0.0 −0.6 −1.2 1.2 0.6 0.0
0.2 −0.4 −1.0 −1.6 0.8 0.2
0.4 −0.2 −0.8 −1.4 −2.0 0.4
 117
−1.5 8.5 3.5 −1.50.0 −5.0 5.0 0.0
1.5 −3.5 −8.5 1.5

0.25 113

−1.0 2.6 1.7 0.8 −0.1 −1.0
−0.5 −1.4 2.2 1.3 0.4 −0.5
0.0 −0.9 −1.8 1.8 0.9 0.0
0.5 −0.4 −1.3 −2.2 1.4 0.5
1.0 0.1 −0.8 −1.7 −2.6 1.0
 13
−0.5 1.5 0.5 −0.50.0 −1.0 1.0 0.0
0.5 −0.5 −1.5 0.5

0.5 19

−1.0 1.8 1.1 0.4 −0.3 −1.0
−0.5 −1.2 1.6 0.9 0.2 −0.5
0.0 −0.7 −1.4 1.4 0.7 0.0
0.5 −0.2 −0.9 −1.6 1.2 0.5
1.0 0.3 −0.4 −1.1 −1.8 1.0
 119
−4.5 9.5 2.5 −4.50.0 −7.0 7.0 0.0
4.5 −2.5 −9.5 4.5

1.0 17

−1.0 1.4 0.8 0.2 −0.4 −1.0
−0.5 −1.1 1.3 0.7 0.1 −0.5
0.0 −0.6 −1.2 1.2 0.6 0.0
0.5 −0.1 −0.7 −1.3 1.1 0.5
1.0 0.4 −0.2 −0.8 −1.4 1.0

−0.3 0.5 0.1 −0.30.0 −0.4 0.4 0.0
0.3 −0.1 −0.5 0.3

Table 5. Coefficient matrices for designs SW(5) and SW(3) analysed with random effects with V ∝ (1− ψ)I6 + ψJ6,6
(Scalings chosen so that entries to 1 d.p. are exact)
Under this model the vector of NSnT responses has dispersion INS ⊗ Ω where Ω is the nT × nT dispersion matrix of
the responses on a cluster, and
Ω =

U W · · · W
W U · · · W
...
...
W W · · · U

where W = δ2IT + τ2JT,T and U = (ν2 + δ2)IT + (ω2 + τ2)JT,T . From this it follows that the dispersion of the T -
dimensional vector of mean responses on a cluster allocated to sequence s, Y¯si is (n−1ν2 + δ2)IT + (n−1ω2 + τ2)JT,T ,
i.e. the same form as for the cross-sectional design, but with τ2 replaced by τ2 + n−1ω2, and ν2 by ν2 + nδ2. More detailed
algebra shows that in the longitudinal case, and for dependencies of the form induced by the model in (6), the estimates of
γ are of the form in (4), but now with ψ = (nτ2 + ω2)/(nτ2 + nδ2 + ω2 + ν2), in the definition of V . Consequently the
above coefficient matrices also apply to the longitudinal case, provided that the appropriate adjustment is made to ψ.
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4. Variance of the treatment estimator under a variety of models
In this section an expression for the variance of θˆ is derived in terms of the coefficient matrix and this is used to explore the
effect of mis-specification of the dispersion structure. To be specific it is supposed that the true ICC is ρ, while that used for
estimation of θ is ρ′. The notation for the matrix in (5) is extended to ast(ρ) in order to make explicit the correlation used
in the estimation. Strictly speaking ast is a function of ψ, which depends on both ρ and n, however the dependence on ρ is
emphasised and that on n is suppressed, as mis-specification in the ICC ρ is more pertinent and familiar to practitioners.
While the results apply to both cross-sectional and longitudinal cases, the exposition below will be in terms of the former.
If we write the S × T coefficient matrix in (5) as a(ρ), where (a(ρ))st = ast(ρ), then the estimator of θ found when the
correlation is taken to be ρ′ is
θˆρ′ =
∑
s,t
ast(ρ
′)(Y¯s)t =
∑
s
as(ρ
′)Y¯s,
where (Y¯s)t is element t of Y¯s and as(ρ′) is the sth row of the coefficient matrix a(ρ′). The subscript ρ′ has been added to
θˆ to emphasise the dependence of the estimator on ρ′. The true variance of Y¯s is 1N V , so it follows that
var(θˆρ′) =
1
N
∑
s
as(ρ
′)V as(ρ′)T =
1
N
tr(a(ρ′)V a(ρ′)T ), (7)
where tr denotes the trace of the matrix. If the true variance has the equicorrelation pattern induced by (2), namely
V = σ2((1− ψ)IT + ψJT,T ), then (7) can be expressed as
var(θˆρ′) =
σ2
N
{(1− ψ)tr[a(ρ′)a(ρ′)T ] + ψtr[(a(ρ′)1T )(a(ρ′)1T )T ]}
=
(τ2 + ν2)
N
{
(1− ρ)
n
tr[a(ρ′)a(ρ′)T ] + ρtr[(a(ρ′)1T )(a(ρ′)1T )T ]
}
As a(ρ′) can be written in terms of aRC and aC , using (5), this expression becomes
Nvar(θˆρ′) = (τ
2 + ν2)
n−1(1− ρ)[(1− b′)2A1 + b′2Q2A2 + 2(1− b′)b′QA3] + ρ(1− b′)2A4
(1− b′ + b′Q)2 , (8)
where
A1 = tr(a
C(aC)T ) A2 = tr(a
RC(aRC)T )
A3 = tr(a
RC(aC)T ) A4 = tr((a
C1T )(a
C1T )
T ),
(9)
and b′ = b′(ρ′) = Tnρ′/(1 + (Tn− 1)ρ′). In (8) A1, . . . , A4 and Q are known values determined by the layout of the
design, and values for classic SWDs, as in Table 1, are given in Table 6 for a range of T . Note that for the cases ρ′ = 0, 1,
var(θρ′) is linearly dependent on ρ.
Analyses based on ρ′ = 0, corresponding to the vertical analysis, on ρ′ = 1, corresponding to the row-column analysis
and on ρ′ = ρ, being the optimal analysis with no mis-specification, are considered. So too are analyses based on
perturbed values of ρ, namely ρ′ = k±1ρ, for k = 2. For these values of ρ′ Figure 1 shows the normalised variances,
(τ2 + ν2)−1Nvar(θˆρ′), for four examples, based on SW(3), SW(9) with n = 5, 50. The ICC in Figure 1 ranges up to 0.3,
which is considerably larger than is usually encountered in practice, but is sufficiently small that kρ < 1.
Figure 1 confirms that the mixed-model estimator (4) using the true correlation for ρ′ has the smallest variance. Even
when ρ′ is perturbed from the true correlation by a factor of 2 the effect on the variance is small: for clarity, only
underestimation, which gives slightly larger variances, is shown in the figure. For T = 4, n = 5 the maximum over ρ ≤ 0.3
of the ratio of the variance when ρ′ = kρ to ρ′ = ρ is 1.060 for k = 12 , whereas the corresponding value for k = 2 is
1.033: for T = 10, n = 5 the values are 1.055 and 1.036, with slightly smaller values when n = 50. If ρ = 0 there is no
clustering effect and the mixed model and vertical models coincide, while the standard row-column analysis has much
8 www.sim.org Copyright c© 201? John Wiley & Sons, Ltd. Statist. Med. 201?, 00 1–21
Prepared using simauth.cls
J. N. S. Matthews and A. B. Forbes
Statistics
in Medicine
T A1 A2 A3 A4 Q
3 2.000 3.000 2.000 2.000 0.667
4 0.750 1.200 0.750 1.125 0.625
5 0.400 0.667 0.400 0.800 0.600
6 0.250 0.429 0.250 0.625 0.583
7 0.171 0.300 0.171 0.514 0.571
8 0.125 0.222 0.125 0.438 0.562
9 0.095 0.171 0.095 0.381 0.556
10 0.075 0.136 0.075 0.337 0.550
11 0.061 0.111 0.061 0.303 0.545
12 0.050 0.092 0.050 0.275 0.542
15 0.031 0.058 0.031 0.215 0.533
20 0.017 0.032 0.017 0.158 0.525
Table 6. Values of traces from (9) and Q for standard stepped wedge designs for various T ≤ 20
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(a) SW(3) with n = 5
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(b) SW(3) with n = 50
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(c) SW(9) with n = 5
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(d) SW(9) with n = 50
Figure 1. N(ν2 + τ2)−1var(θˆρ′) plotted against the true value of ρ: solid line ρ′ = 1 (row-column analysis); dashed and
dotted ρ′ = 0 (vertical analysis); dashed line ρ′ = ρ; dotted line ρ′ = 12ρ. Designs with 4 periods (first row) and 10 periods
(second row) are shown: n = 5 shown in first column and n = 50 in second column.
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larger variance, because it is attempting to eliminate row effects that are, in fact, absent. With increasing clustering the
variance of the vertical estimator increases markedly, and is too inefficient to be viable unless both n and ρ are small. The
efficiency of the row-column estimator increases with increasing ρ; for ρ > 0.2 its variance is less than 10% (T = 4) and
6% (T = 10) larger than the optimal value when n = 5, and only 1% and 0.6% larger when n = 50.
5. Efficient vertical analyses
The so-called vertical analysis is based on the coefficient matrix aC : the ‘vertical’ aspect is that the columns alone sum
to zero, so providing contrasts made between randomized groups in each period of the design. The first and last columns
vanish because there is no variation between treatments in these columns, so θˆ based on aC is a weighted combination of
the T − 2 non-trivial column-wise estimators. The estimator using aC weights the column-wise estimators inversely by
their variance and is optimal in the case when the elements in a row are independent.
0 0.2 0.15 0.10 0.05 0
0 −0.05 0.15 0.10 0.05 0
0 −0.05 −0.10 0.10 0.05 0
0 −0.05 −0.10 −0.15 0.05 0
0 −0.05 −0.10 −0.15 −0.20 0

(a) aC for six-period design

0 0.2λ1 0.15λ2 0.10λ3 0.05λ4 0
0 −0.05λ1 0.15λ2 0.10λ3 0.05λ4 0
0 −0.05λ1 −0.10λ2 0.10λ3 0.05λ4 0
0 −0.05λ1 −0.10λ2 −0.15λ3 0.05λ4 0
0 −0.05λ1 −0.10λ2 −0.15λ3 −0.20λ4 0

(b) Modified vertical analysis
Table 7. Coefficient matrices for vertical analyses of designs SW(5): λi chosen to ensure unbiassedness and minimum
variance when there is within-row correlation
In practice it is not possible to exclude within-row dependence in the outcomes. An alternative approach to providing
a ‘vertical’ analysis is to use the coefficient matrix in table 7(b), where λ1, . . . , λT−2 are chosen to minimise the
variance of θˆ, while maintaining unbiassed estimation of θ. In the following it will be convenient to define a˜ to be the
S × (T − 2)-dimensional matrix obtained by omitting the first and last columns from aC . Also, suppose that X˜ denotes
the S × (T − 2)-dimensional matrix of 0s and 1s showing the SWD, as in Table 1, again with the first and last columns
omitted. If the column weights λ1, . . . , λT−2 are written as a diagonal matrix Λ, then the revised estimator, θˆΛ is that
obtained by using a˜Λ as the coefficient matrix. Also
var(θˆΛ) =
1
N
tr(a˜ΛV˜ Λa˜T ) =
1
N
tr(ΛV˜ ΛB)
and for unbiassedness
1 = tr(a˜ΛX˜T ) = tr(ΛX˜T a˜),
where B = a˜T a˜ and V˜ is the dispersion matrix for the cluster means in periods 2 to T − 1, i.e. V˜ is V with the first & last
rows and the first & last columns omitted. To minimise var(θˆΛ), introduce the Lagrange multiplier µ and Lagrangian
L = tr(ΛV˜ ΛB)− µ(tr(ΛX˜T a˜)− 1)
and
∂L
∂λk
= 2tr(ekV˜ ΛB)− µtr(ekX˜T a˜), k = 1, . . . , T − 2
where ek is a (T − 2)× (T − 2) matrix of zeroes except that element (k, k) is 1. The first term on the LHS is 2
∑
j v˜kjbkjλj
and the second term is the kth diagonal element of X˜T a˜, which we collect together as a (T − 2)-dimensional vector d.
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Writing V˜ ◦B for the Hadamard, or element-wise product of V˜ and B, the optimal λ is
λopt =
(V˜ ◦B)−1d
dT (V˜ ◦B)−1d .
If V˜ is of the form ω1IT−2 + ω2JT−2,T−2, then V˜ ◦B = ω1diag(B) + ω2B, where diag(·) denotes the diagonal elements
of its argument. Using this form it can be shown that (ω1diag(B) + ω2B)1T−2 ∝ d, in other words for equicorrelation
dependence, the optimum vertical analysis sets all λi = 1, i.e. to use the vertical analysis derived in Section 2 based on
aC . This does not have to apply if V˜ takes another form: for example with T = 6 and V having an autocorrelation structure
with Vij = ρ|i−j|, then for ρ = 12 the optimal λs are 1.108, 0.929, 0.929, 1.108. However, in this case the distinction is
slight, because the efficiency of the equally weighted analysis is around 99.6%.
The above indicates that for the equicorrelation structure the equally weighted vertical analysis, shown to be generally
very inefficient in Section 4 is, nonetheless, the best of the extended vertical analyses exemplified in Table 7(b). It is only
slightly suboptimal amongst vertical analyses when an autoregressive dispersion model is assumed, which demonstrates
that even the best extended vertical analysis is highly inefficient for some plausible dispersion structures.
6. Extended SWDs with multiple treatments
6.1. Row-column and vertical analyses
Although the classic form in Table 1 dominates the literature on SWDs, numerous variants are possible, several of which
fit into the framework of the present paper. The extensions considered in this section are to designs where a standard
treatment, 0, is compared with two new treatments, denoted by 1 and 2. There are several types of such designs, each
potentially of use in a variety of settings. Lyons and colleagues [12] present and categorise various extensions of this type,
and cite four trials where these extensions either have been used or might profitably have been used [13, 14, 15, 16].
Time
Sequence 1 2 3
1 0 1 1
2 0 0 1
3 0 2 2
4 0 0 2
Table 8. Concurrent stepped wedge design with T = 3 periods, S = 4 sequences comparing a standard treatment 0 with
two new treatments 1 & 2.
The first extension is the concurrent design, shown in Table 8 for three periods, which is essentially two separate SW(2)
designs each testing a different new intervention. Although these assessments could be made in two separate classic SW(2)
designs, it may be sensible to combine them as each new treatment is compared with the same standard treatment, and
if it is reasonable to believe that the same period effects extend across the two component SW(2) designs. In this case a
suitable extension to the model in (1) is
Yst = αs + βt +D1stθ1 +D2stθ2 + ηst (10)
where Dkst = 1 if treatment k ∈ {1, 2} is allocated to cell (s, t), and 0 otherwise: here θk is the effect of treatment k
relative to treatment 0.
Two further extensions considered in [12] are the replacement and supplementation designs, shown in Table 9 for the
case T = 6. It is suggested [12] that the replacement design would be useful when there are two interventions to assess but
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Time
Sequence 1 2 3 4 5 6
1 0 1 1 2 2 2
2 0 0 1 1 2 2
3 0 0 0 1 1 2
(a) Replacement design for T = 6
Time
Sequence 1 2 3 4 5 6
1 0 1 1 1+2 1+2 1+2
2 0 0 1 1 1+2 1+2
3 0 0 0 1 1 1+2
(b) Supplementation design for T = 6
Table 9. Replacement and Supplementation designs for comparing two new treatments with a standard
which cannot be applied at the same time. It is conceded that there must be no carryover from the periods when intervention
1 is used into those when intervention 2 is employed. In many service implementation studies the new arrangements may
take some time to become familiar, so a further use of the replacement design could be practical way to allow for this
effect, by conceiving of treatment 2 as a mature version of treatment 1, as has been previously suggested [10, 17].
The supplementation design would be suitable when a second intervention requires that the first is present, or where the
first cannot be removed once it has been implemented. Mathematically the design is largely the same as the replacement
design, as from this point of view the difference between the designs amounts to a re-parametrization of the treatment
effect. In the supplementation design θˆ2 is θˆ2 − θˆ1 in the replacement design.
Other extensions are mentioned in [12], such as a factorial design; the approach described below can also be applied to
these designs and they will be explored elsewhere.
The row-column and vertical analyses described in Section 2 can be applied to these extended designs if the model in
(10) is adopted. The estimator of (θ1, θ2)T is derived in (A3) and, as for the two-treatment case, can be expressed in terms
of coefficient matrices. These can be written in terms of the coefficient matrices for two sub-designs,D1 andD2 of a three
treatment design D: cell (s, t) of D1(D2) is 1 if treatment 1(2) is applied in that cell and 0 otherwise. If the coefficient
matrices for D1 and D2, regarded as two-treatment designs, are a(1) and a(2) respectively then the coefficient matrices
for (θˆ1, θˆ2) from D can be written as (
θˆ1
θˆ2
)
= M˜−1
[
a(1)
a(2)
]
.
As a(1), a(2) are S × T matrices, the [] are a reminder that this equation must be interpreted formally, namely as the
implied linear combination of the coefficient matrices: cf. (A4). The matrix M˜ is(
1 r1
r2 1
)
,
so, for example, the coefficient matrix for θˆ1 is [a(1)− r1a(2)]/(1− r1r2). The elements r1 and r2 differ depending on
whether the row-column or the vertical analysis is used. In addition, the dispersion matrix of the estimators can also be
found as:
var
(
θˆ1
θˆ2
)
=
σ2η
N
M˜−1
(
tr(a(1)a(1)T ) tr(a(1)a(2)T )
tr(a(1)a(2)T ) tr(a(2)a(2)T )
)
M˜−1T . (11)
For the concurrent design the coefficients and dispersion matrices are shown in Table 10 for both the row-column and
vertical analyses. The variance of θˆ1 from a design which comprised just the first two rows from Table 8 would be
3σ2η for the row-column analysis and 2σ2η for the vertical analysis. Consequently, while an investigator assessing two
interventions against the same standard treatment might use a row-column analysis of two separate SW(2) designs,
obtaining var(θˆ1) = v, the same resources could give a variance of 1524v if the concurrent design in Table 8 were used.
In this case the investigator would have to be persuaded that the period effects βt could be assumed to apply to the whole
design, because it is the availability of information on these parameters from all the rows in Table 8 which gives rise to
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the more precise treatment estimator.
Coefficient matrices 18
−4 5 −11 −5 40 3 −3
3 −3 0
 16
0 4 10 −3 10 2 −1
0 −3 −1

σ−2η var
(
θˆ1
θˆ2
)
1
8
(
15 9
9 15
)
1
6
(
7 5
5 7
)
(a) (b)
Table 10. Coefficient matrices for θˆ1 for the concurrent design in Table 8: (a) row-column and (b) vertical analyses. The
coefficient matrices for θ2 are the same but with the first two rows interchanged with the second two rows. The dispersion
matrices for (θˆ1, θˆ2)T for these models are shown below the coefficient matrices
The coefficient and dispersion matrices for the Replacement design (Table 9(a)) are shown in Table 11. As remarked
in [12], while the concurrent design gives θˆ1 and θˆ2 that have equal precision, the replacement design gives an estimate
of θˆ2 which is notably less precise than θˆ1. Although the two treatments are equally replicated, in the replacement design
treatment 2 is more heavily confounded with period effects than treatment 1. The estimates of the two treatment effects
are highly correlated in both row-column and vertical analyses. It is worth noting that the coefficient matrices in Table 11
contain a number of zeroes, corresponding to observations that will be ignored in the analysis. This is more marked for
the vertical analysis but nonetheless there are a number of observations which contribute nothing even in the row-column
analysis.
Replacement Design
Sequence 1 0 1 1 2 2 2
Sequence 2 0 0 1 1 2 2
Sequence 3 0 0 0 1 1 2
θˆ1
1
8
−2 4 1 0 −1 −20 −3 3 −1 1 0
2 −1 −4 1 0 2
 1
4
0 2 1 0 0 00 −1 1 0 0 0
0 −1 −2 0 0 0

θˆ2
1
2
−1 1 0 1 0 −10 −1 1 −1 1 0
1 0 −1 0 −1 1
 1
4
0 2 1 2 1 00 −1 1 −1 1 0
0 −1 −2 −1 −2 0

σ−2η var
(
θˆ1
θˆ2
)
1
8
(
9 12
12 24
)
1
8
(
9 3
3 9
)
1
4
(
3 3
3 6
)
1
4
(
3 0
0 3
)
(a) (b)
Table 11. Coefficient and dispersion matrices for the row-column (a) and vertical (b) analyses of the six-period
replacement SW design: note italicised disperson matrices in last row relate to the Supplementation design.
The corresponding results for the Supplementation design, Table 9(b), are not shown because they are closely related
to those for the Replacement design. In an obvious notation, θSupp1 = θ
Rep
1 and θ
Supp
2 = θ
Rep
2 − θRep1 , so if the coefficient
matrices from the Replacement design for θ1 and θ2 are, respectively a
Rep
1 and a
Rep
2 , then the corresponding matrices
for the Supplementation design are aSupp1 = a
Rep
1 and a
Supp
2 = a
Rep
2 − aRep1 . Moreover this connection between the
parameters allows the variances for the supplementation design to be found, as shown in italics in Table 11: note that in this
parameterisation θ1 and θ2 are estimated with equal precision and are markedly less correlated than for the Replacement
design.
6.2. Random effects analyses
The random effects model described in Section 3.1 carries over to the extended designs in a natural way. If the analysis of
an extended design D uses the correlation ρ′ and the coefficient matrices for the sub-designs D1 and D2 are a(ρ′, 1) and
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a(ρ′, 2) respectively, then the estimators for the treatment effects are(
θˆρ′1
θˆρ′2
)
= M˜−1
[
a(ρ′, 1)
a(ρ′, 2)
]
(12)
where now
M˜ =
(
1 Q˜1
1−b′+b′Q12
1−b′+b′Q1
Q˜2
1−b′+b′Q12
1−b′+b′Q2 1
)
and, as before, b′ = Tnρ′/(1 + (Tn− 1)ρ′) and the Qs are defined at the end of Appendix 1. The dispersion matrix of
(θˆρ′1, θˆρ′2)
T also carries over from the uncorrelated case so, using the new form for M˜ , we have from (11) that
var
(
θˆ1
θˆ2
)
=
1
N
M˜−1
(
tr(a(ρ′, 1)V a(ρ′, 1)T ) tr(a(ρ′, 1)V a(ρ′, 2)T )
tr(a(ρ′, 1)V a(ρ′, 2)T ) tr(a(ρ′, 2)V a(ρ′, 2)T )
)
M˜−1T ,
where V is the true variance, as used in (7).
ψ′ Coefficients combined Coefficients separate
0.0 16
0 4 10 −3 10 2 −1
0 −3 −1
 (0 1 00 −1 0
)
0.05 11281
−51.5 850.5 179.520.0 −651.0 251.0−9.5 430.5 −240.5
41.0 −630.0 −190.0
 121 (−1 21 −11 −21 1
)
0.1 1341
−26.5 225.5 39.510.0 −176.0 76.0−4.5 115.5 −70.5
21.0 −165.0 −45.0
 111 (−1 11 −11 −11 1
)
0.25 113
−2.3 8.5 0.70.8 −7.0 3.8−0.3 4.5 −3.3
1.8 −6.0 −1.2
 (−0.2 1 −0.20.2 −1 0.2
)
0.5 121
−6.5 13.5 −0.52.0 −12.0 8.0−0.5 7.5 −6.5
5.0 −9.0 −1.0
 13 (−1 3 −11 −3 1
)
1.0 14
−2.0 2.5 −0.50.5 −2.5 2.00.0 1.5 −1.5
1.5 −1.5 0.0
 (−0.5 1 −0.5−0.5 −1 0.5
)
Table 12. Coefficient matrices for θˆ1 for the three-period concurrent design in Table 8 using random effects model (left
hand column). Although the matrices, a(ρ′, 1), a(ρ′, 2) are written in terms of ρ′ for consistency with Section 4, they are
functions of ρ′ and n through ψ′ = nρ′/[(1− ρ′) + nρ′], which is used to index this table. Coefficients for SW(2) (right
hand column) shown for comparison.(Scalings chosen so that entries to 1 d.p. are exact)
If an investigator wishes to assess three treatments using the design D in Table 8, then the treatment estimator can
be based on an analysis of the whole design, using the coefficients in the left-hand column of Table 12. An alternative
approach would be to analyse the component designs separately, using the coefficients in the right-hand column of Table
12. This might be adopted if the analyst is unsure if the period effects can be taken to be the same across D1 and D2. As
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with the classic design, information from the first period is ignored when ρ′ = ψ′ = 0, but in the combined analysis, it is
no longer necessary to ignore information from period 3. Again, when ρ′ = ψ′ = 1 the coefficients within a sequence will
always sum to 0. For intermediate values the pattern of coefficients changes smoothly from one extreme analysis to the
other.
Assuming that equal numbers are allocated to all the sequences inD, the variances of θˆ1 from the combined and separate
analyses can be compared and the ratio of these two quantities is plotted in Figure 2(a) for the design in Table 8. With
this formulation the effect of mis-specification of ρ could be investigated, but this is not considered in Figure 2 where ρ′
is assumed to be equal to the true correlation ρ. The design in Table 8 combines two copies of SW(2), and Figure 2 also
shows the results for the analogous designs based on SW(5) and SW(11). The advantage of using the combined design
reduces with increasing ρ but even for ρ close to 0.3 the separate analysis has a variance between 1.4 and 1.6 times larger,
with the larger advantage occurring for shorter designs.
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(a) Variances of θˆ1 (or θˆ2)
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(b) Variances of θˆ1 − θˆ2
Figure 2. Ratio of variances separate:combined, for designs with 3, 6 and 12 periods: solid lines, n = 5 for solid and
n = 50 for dashed lines
If there is interest in estimating θ1 − θ2 then the combined analysis analysis offers a much more efficient estimator than
simply taking the difference of the estimators from the separate analyses. The corresponding variance ratios for θˆ1 − θˆ2
are show in Figure 2(b): while the overall pattern is similar, the ratios indicate a much larger advantage for the combined
analysis.
7. Discussion
In stepped wedge trials the usual precepts of design theory have to be sacrificed to meet the practical constraints of the
applications where they are typically used. Nevertheless a SWD is still an experimental design and some of its properties
can best be understood by viewing it in this light. In particular, because of the marked non-orthogonality between the
period effects and the treatment effect inherent in a SWD, it is useful for the triallist to understand how the observations
are combined to provide a treatment estimator for each of the several forms of analysis that are available. The coefficient
matrices derived in Sections 2, 3.1 and 6 allow the user to see how the information in the different cells of the table are
combined to provide θˆ: Kershner and Federer [18] provided similar information for two-treatment crossover designs. The
treatment estimators obtained from most designed experiments apply quite similar weights to the observations, as shown
in Table 3(b). This is not the case for SWDs: several of the coefficient matrices shown in the present paper reveal that
many observations receive relatively low weight, or have coefficents with counterintuitive signs, and some observations
are ignored altogether. Of course, more efficient and balanced designs, such as NrO, are not alternatives to SWDs because
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they do not fulfil some of the requirements such as treatments changing from 0 to 1 only once in a sequence, which in
practice corresponds to a new intervention not being able to be withdrawn once it has been implemented. Nevertheless, it
is important for users of SWDs to be aware of the statistical consequences of their choice of design.
The coefficient matrices presented in this paper assume that the number of clusters in a sequence, N , and the number of
observations in each period within each cluster, n are constant. In practice this will not be the case, but i) departures will
often be small, and ii) this assumption provides coefficients which are easily assimilated, thereby giving greater insight
into the way SWDs provide information on the treatment effects.
For designs comparing two treatments the coefficients are often simpler for the vertical analysis. However, as Figure
1 shows, the vertical analysis produces the most precise estimator only if there is no variation between clusters. As the
contribution of the between-cluster variation to the total variation in the cluster means Y¯is increases, the vertical analysis
rapidly produces a very much less precise estimator than a mixed-effects or row-column analysis. Substantial values of ψ
are likely to be a feature of many SWDs, especially those with larger values for n, so the efficient use of these designs will
require the analyst to accept the unbalanced contrasts, such as those shown in Table 5.
The results in Sections 3 and 4 are largely based on the form for V induced by (3), although similar results would obtain
for the extensions described in Section 3.2. However there may be good reason to consider other forms for V , such as
ones where cluster effects are less correlated the further they are separated in time. Such V could be used in (4) although
analogues of the subsequent algebraic results would only be available if the revised V possessed an explicit inverse. We
hope to report on the application of autoregressive processes to these designs in the near future.
The extended designs proposed in [12] and discussed in Section 6 represent quite a new line of work but may offer
substantial advantages in certain contexts. In particular the concurrent design, running two SWDs in parallel, allows
period effects to be eliminated more efficiently, and, if relevant, the two new treatments can be compared much more
efficiently. The Replacement design, Table 9(a), allows a second new treatment to follow the first. However, if it is not
imperative that all clusters end the trial receiving the second treatment, then other forms of the design may have merit.
For example, if the middle sequence in Table 9(a) were permitted to be 0, 0, 2, 2, 1, 1, then var(θˆ1) decreases by 8% and
var(θˆ2) by 49%; the large reduction for θ2 is because in the new design there is much less confounding of the information
on θ2 with the period effect. If a need for designs of this kind were established, then further exploration of their precise
form could pay substantial dividends.
Other forms of SWD have also been discussed, some of which fit into the framework derived above, such as hybrid
designs [3], where the classic SWD is supplemented with a number of sequences in which only treatment 0, or only
treatment 1 is used, so it is a mixture of a SWD with a standard cluster randomized trial. In the classic SWD the number
of periods is one more than the number of sequences, because the changeover from standard to new treatment advances
by one period every sequence. However, this pattern can be modified, as shown in [3] and provided observations are made
in every period and every sequence, the coefficient matrices can be derived using the methods in Section 2. Other patterns,
such as periods where no observations are taken in some sequences, feature in some designs[19], where such interludes
are used to accommodate training sessions; the methods in Sections 2 and 3 would need some adaptations to deal with
such cases.
The possibility that responses may vary over time, as well as because of changes in treatment, means that a model which
allows for time effects is essential. The same is true of crossover trials, where the prudent analyst may wish to include
period effects. The usual way that time is taken into account is through the term βt in (2). Non-standard approaches can be
used if a specially tailored model can be identified for a particular application [20], but this is the exception not the rule.
In crossover trials empirically determined departures from the standard model are seldom encountered because crossover
studies usually recruit too few subjects to permit a secure exploration of alternative models. The position with SWDs may
be somewhat different, as these trials will often be much larger and the data might suggest models that are better than
that in (2). Allowing for time by replacing the categorical variables with a simple trend has been mentioned [12] as one
possibility, although other forms might be contemplated. Moreover, it may be plausible in some applications to assume
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that the effect of time varies between clusters, as described in Section 3.2. Obviously there would be dangers in using the
data from a particular study to determine its analysis, but as experience accrues in a particular field, useful information
could emerge.
In the early development of crossover trials it was usually assumed that treatment effects might carry over into the
immediately succeeding period, in a way described by a simple model [21]. More recently there has been substantial
criticism of the applicability of such a model [6, 22], and approaches in which carryover effects are excluded by non-
statistical methods, such as washout periods, have found favour. This is another aspect where the small size of crossover
trials has inhibited attempts to identify alternative models by empirical exploration of data.
In classic SWDs something directly analogous to a carryover cannot arise because the new treatment is never followed
by any other treatment (although issues may arise for the designs in Section 6). What can arise is that the effect of the
new treatment changes in the time shortly after the changeover in treatments. Such an effect might happen if, for example,
staff delivering a new treatment become more proficient as they become more accustomed to a new way of working [7].
Wash-in periods in SWDs, placed just after the change in treatment when staff get used to the new treatment but the data
are not analysed, is a design device to mitigate this problem, analogous to the well-established use of wash-out periods
in crossovers. An alternative approach [10, 23, 17] is to use (2) but with values of Dst other that 0 or 1. For example
fractional Dst might be specified just after the treatment changes over, perhaps increasing to 1 in steps defined by the
analyst. In such circumstances much of the work in the present paper would carry over with only minor adjustments. For
example, the matrix aRCst is still more or less as implied by (A1), namely
aRCst =
STDst − SR1s − TC1t +G1
STG˜1 − SRT1 R1 − TCT1 C1 +G21
,
with the obvious caveats that R1(C1) are the row(column) sums of the Dst and G1 =
∑
s,tDst. The main change is that
the first G1 on the denominator of (A1) changes to G˜1 =
∑
s,tD
2
st. Clearly G1 and G˜1 coincide when Dst ∈ {0, 1} but
not otherwise. Likewise, the formula for var(θˆ) in [10] can be used for general Xij given a similar amendment, namely
that
var(θˆ) =
Iσ2(σ2 + Tτ2)
(IU˜ −W )σ2 + (U2 + IT U˜ − TW − IV )τ2
where U˜ =
∑
i,j X
2
ij .
In summary, this paper describes the stepped wedge design in terms of experimental design concepts, which has enabled
the form and nature of the treatment effet estimator to be made explicit and its properties more clearly understood.
Statist. Med. 201?, 00 1–21 Copyright c© 201? John Wiley & Sons, Ltd. www.sim.org 17
Prepared using simauth.cls
Statistics
in Medicine J. N. S. Matthews and A. B. Forbes
Appendix 1: derivation of coefficient matrix for row-column design
Two-treatment case
Starting from a row-column design with S rows and T columns comparing two treatments, and with a single continuous
outcome yst in the sth row and tth column, then the model in (1) can be written in matrix form as y = Xζ + η, where the
parameters are written in vector form as ζT = (αT , βT , θ) and the design matrix is
X =
(
IS ⊗ 1T 1S ⊗ IT D1
)
,
where D1 is an ST -dimensional vector of 0s and 1s indicating treatment allocation and 1m denotes an m-dimensional
vector of 1s. The least squares estimator of ζ is (XTX)−XT y, where A− is a g-inverse of A: in order to obtain an
expression for the estimator of θ, we need to consider partitions of (XTX)− and XT y. If we denote the m× n matrix of
1s by Jm,n, then
XTX =
TIS JS,T R1JT,S SIT C1
RT1 C
T
1 G1
 ,
where R1 (C1) is an S (T )-dimensional vector giving the number of times treatment 1 appears in each row (column), and
G1 is the number of times treatment 1 appears in the whole design. One of the steps in finding an expression for θˆ is to
invert this matrix and this is facilitated by noting that a g-inverse of the leading (S + T )× (S + T ) sub-matrix of XTX is(
TIS JS,T
JTS,T SIT
)−
=
(
1
T IS − aJS,S 1(S+T )2 JS,T
1
(S+T )2 J
T
S,T
1
S IT − bJT,T
)
where
a =
2T + S
T (S + T )2
and b =
2S + T
S(S + T )2
.
Application of standard results on partitioned matrices then shows that the estimate of the treatment effect from the
row-column model is
θˆ =
STy(1) − SRT1 yR − TCT1 yC +G1yG
STG1 − SRT1 R1 − TCT1 C1 +G21
, (A1)
where y(1) is the sum of the yst which have received treatment 1, yR is the vector of row sums of the yst, i.e. the sth
element of yR is
∑T
t=1 yst and yC is the vector of column sums, and yG is the sum of all the yst. From this it can be seen
that the coefficient matrix aRCst is proportional to STDst − SR1s − TC1t +G1.
The corresponding expression when the row effect is omitted from the model is
θˆ =
Sy(1) − CT1 yC
SG1 − CT1 C1
, (A2)
indicating that aCst is now proportional to SDst − C1t. For the case of three treatments, and for the case of random cluster
effects, it is useful to make the following definitions: dRC as the denominator of (A1), dC to be T times the denominator
of (A2) and Q = dRC/dC .
Three-treatment case
For row-column designs which compare a standard treatment with two new treatments, the design matrix can be extended
to
X =
(
IS ⊗ 1T 1S ⊗ IT D1 D2
)
,
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where the effects are θˆ1 and θˆ2 (no interaction is considered) and the ST -dimensional vectors D1 and D2 describe the
allocation of treatments 1 and 2 in the design. Suppose R2, C2 and G2 are defined as the analogues of R1, C1 and G1 for
treatment 2, and G12 is the number of cells where treatments 1 and 2 are both allocated. The estimator of (θ1, θ2)T is(
θˆ1
θˆ2
)
= M−1
(
STy(1) − SRT1 yR − TCT1 yC +G1yG
STy(2) − SRT2 yR − TCT2 yC +G2yG
)
(A3)
where
M = ST
(
G1 G12
G12 G2
)
+
(
G21 G1G2
G1G2 G
2
2
)
− S
(
RT1 R1 R
T
1 R2
RT1 R2 R
T
2 R2
)
− T
(
CT1 C1 C
T
1 C2
CT1 C2 C
T
2 C2
)
,
and y(2) is the sum of observations receiving treatment 2. The coefficients aRCst can then be identified using the approach
used for the two-treatment case. The result for three treatments when the row effect is omitted is
θˆ =
[(
G1 G12
G12 G2
)
− 1
S
(
CT1 C1 C
T
2 C1
CT2 C1 C
T
2 C2
)]−1 [(
y1
y2
)
− 1
S
(
CT1 yC
CT2 yC
)]
.
If D is a design with three treatments, then the coefficient matrices for θˆ1 and θˆ2 can be written as linear combinations of
the coefficient matrices, a(1) and a(2) for, respectively, the two-treatment sub-designs, D1 and D2 defined in Section 6.1.
As stated above we have (
θˆ1
θˆ2
)
= M˜−1
[
a(1)
a(2)
]
, (A4)
where the [] indicate that this should be interpreted as the linear combination of the matrices, i.e., that the coefficient
matrix for θˆ1 is m˜11a(1) + m˜12a(2), where m˜ij are the elements of M˜−1. The matrix M˜ is defined as(
1 Q˜1
Q˜2 1
)
(vertical analysis) or
(
1 Q˜1Q12Q1
Q˜2Q12
Q2
1
)
(row-column).
Here Q1 is the value of Q the sub-design D1 and Q2 is the corresponding quantity for D2. For three-treatment designs we
also need Q12, defined as
d12C = STG12 − TCT1 C2; d12RC = STG12 − SRT1 R2 − TCT1 C2 +G1G2; and Q12 = d12RC/d12C .
Also with d1C(d
2
C) defined as dC for sub-design D1(D2), write Q˜1 = d
12
C /d
1
C and Q˜2 = d
12
C /d
2
C .
Appendix 2: row-column designs with correlated rows
Two-treatment case
If Ys = (ys1, ys2, . . . , ysT )T is written for the mean of the N clusters on sequence s then cov(Ys) = V/N . If a model
with column effects is fitted using (4), where Xs = (IT | D1s), with D1s being the T -dimensional part of D1 describing
allocations in sequence s, then, using results for partitioned matrices once more we find
θˆ =
S
∑S
s=1D
T
1sV
−1Ys − CT1 V −1YC
S
∑S
s=1D
T
1sV
−1D1s − CT1 V −1C1
(A5)
with YC denoting the vector of
∑S
s=1 yst, t = 1, . . . , T .
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If V = σ2((1− ψ)Ic + ψJc,c) a formula for θˆ can be derived by evaluating V −1 and substituting in (A5). Note that
V −1 =
1
σ2(1− ψ) [Ic −
b
T Jc,c] with b =
Tψ
1 + ψ(T − 1)
In substituting this expression in (A5) the factor σ−2(1− ψ)−1 cancels, so can be ignored in the calculations. This gives
θˆ =
STy(1) − TCT1 YC − b[SRT1 YR −G1YG]
STG1 − TCT1 C1 − b[SRT1 R1 −G21]
=
(1− b)[STy(1) − TCT1 YC ] + b[STy(1) − TCT1 YC − SRT1 YR +G1YG]
(1− b)[STG1 − TCT1 C1) + b[STG1 − TCT1 C1 − SRT1 R1 +G21]
.
Comparing the elements of this expression with those for the vertical and row-column analyses, namely (A1) and (A2), it
is readily seen that the above estimator can be written as a weighted mean of the vertical and row-column estimators, and
that the coefficient matrix can be written as (5).
Three-treatment case
The result for three treatments proceeds analogously, giving(
θˆ1
θˆ2
)
= M−1
(
STy(1) − TCC1 yC − b[SRT1 yS −G1yG]
STy(2) − TCC2 yC − b[SRT2 yS −G2yG]
)
(A6)
where
M = ST
(
G1 G12
G12 G2
)
− T
(
CT1 C1 C
T
1 C2
CT1 C2 C
T
2 C2
)
− b
[
S
(
RT1 R1 R
T
1 R2
RT1 R2 R
T
2 R2
)
−
(
G21 G1G2
G1G2 G
2
2
)]
If Mij denotes the (i, j)th element of M , then the elements of the vector on the right hand side of (A6), divided,
respectively, by M11 and M22, are the estimators of θ1, respectively θ2, from the sub-designs D1 and D2. These can
be re-cast as coefficient matrices and so provide the expression in (12).
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